Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
about
Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@en
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@nl
type
label
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@en
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@nl
prefLabel
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@en
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Indirect comparison of efficac ...... ed non-small-cell lung cancer.
@en
P2093
Chin-Chuan Hung
Jia-Lian Yang
Jin-Hua Chen
Jiun-Yi Wang
P2860
P356
10.1038/S41598-018-27994-X
P407
P50
P577
2018-06-26T00:00:00Z